Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of Persistent Chemotherapy-Induced Thrombocytopenia

esmo - Findings from the RECITE study

AI Summary: A clinical study found romiplostim effective in treating and preventing recurrent persistent chemotherapy‑induced thrombocytopenia, restoring platelet counts and enabling continuation of scheduled cytotoxic therapy. Patients experienced fewer delays and dose reductions, positioning romiplostim as a useful strategy to keep chemo on track—because, apparently, platelet math still runs cancer care.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks

Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks

Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma / 2 months

Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 4 hrs

DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 36 hrs